Moreover, it should be noted that the increased risk of adverse events (e.g., atrial fibrillation) by BTK inhibitors is counterbalanced by risk factors normally encountered in the general population and more specifically in CLL patients (older age, male sex, baseline platelet dysfunctions observed in CLL itself).53 The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.